| Project/Area Number |
21590187
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Hyogo University of Health Sciences |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SANO Hajime 兵庫医科大学, 医学部, 教授 (00196304)
FUJIMOTO Jiro 兵庫医科大学, 医学部, 教授 (90199373)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MATSUMOTO Kunio 金沢大学, がん研究所, 教授 (90201780)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 関節リウマチ / 滑膜 / 血管新生 |
|---|
| Research Abstract |
Intravenous injection of AdCMV. NK4 into SKG mice suppressed the progression of s-glucan induced arthritis. Bone destructions were also inhibited by NK4 treatment. Histopathological findings of the foot joints revealed that angiogenesis, inflammatory cytokines, and RANKL expressions in synovial tissues were significantly inhibited by NK4 treatment. Molecular targeting of HGF by NK4 can therefore be potentially applied as a novel therapeutic approach for the treatment of RA.
|
